Maze Therapeutics presents MZE829 data showing 36% mean reduction in proteinuria in evaluable AMKD patients
MAZE•Maze Therapeutics reported a 36% mean reduction in urine albumin-to-creatinine ratio among 12 evaluable AMKD patients in the Phase 2 HORIZON trial; no serious adverse events were reported. The company expects data from all three cohorts in early 2027 and is targeting pivotal trial initiation in the first half of 2027, subject to regulatory feedback.
1. MZE829 trial results
Maze Therapeutics said enrollment in the Phase 2 HORIZON trial is complete, with more than 50 patients. Initial results showed a 36% mean reduction in urine albumin-to-creatinine ratio across 12 evaluable AMKD patients, and no serious adverse events were reported. Data from all three cohorts are expected in early 2027.
2. Other programs and cash
The company is targeting initiation of a pivotal MZE829 trial in the first half of 2027, subject to regulatory feedback. Its MZE782 phenylketonuria trial is enrolling, with topline data expected in 2027, and a chronic kidney disease trial is planned for the first half of 2027. Maze said its expected cash runway extends into 2029 based on its current business plan.
